AI-driven solutions and services provider Saama has announced the introduction of Clinical AI Agents — a modular, industry-first approach to rapidly increase innovation and efficiency for existing platform investments. These Clinical Agents, developed using Saama’s existing Agentic AI platform, are designed to operate with partial autonomy, allowing them to still function under the appropriate level of human oversight and controls. These agents also offer seamless integration with Saama’s Digital Study Platform to increase efficiency within clinical development value chains from Study Start to Submission, and provides users with the ability to use either individual agents or complete agentic workflows, depending on their individual needs.
Chief Executive Officer Bhaskar Sambasivan expressed his enthusiasm with the new technology, stating, “By introducing these AI agents, backed by a modular framework, [Saama will] enable our customers to engage in rapid innovation on top of their existing platform investments, accelerating time and reducing effort and costs.”
Saama’s Chief Products and Innovation Officer Prasanna Rao also shared his excitement about the announcement, adding, “With [Saama’s] focus on compliant and responsible AI, we are overcoming the barriers that have stalled most enterprise AI initiatives and setting a new standard for clinical development.”
Founded in 1997 and located in Campbell, CA, Saama has spent nearly 30 years developing life science solutions using innovative technologies across clinical and commercial operations. For more information on this story, view the company’s press release and other related materials below.
See related materials: